Janus kinase 2
About 🧾
- Janus Kinase 2 (JAK2): A protein tyrosine kinase that mediates cytokine receptor signalling.
- Essential for hematopoiesis, immune regulation, and cell growth.
- Part of the JAK-STAT pathway → transduces signals from cytokines and growth factors.
Aetiology 🧬
- JAK2 Gene: Encodes a cytoplasmic kinase involved in blood cell formation.
- Hematopoietic stem cells: Differentiation into:
- 🩸 Red blood cells (erythrocytes).
- 🛡️ White blood cells (leukocytes).
- 🧩 Platelets (thrombocytes).
Key Mutation: JAK2 V617F ⚡
- Essential Thrombocythaemia (ET): ~50% of cases.
- Polycythaemia Vera (PV): ~95% of cases (diagnostic hallmark).
- Primary Myelofibrosis (PMF): ~50% of cases.
Clinical Relevance 🩺
- Gain-of-function mutation → constitutive activation of JAK-STAT.
- Causes excessive proliferation of blood cells.
- Leads to:
- Thrombosis risk 🧨.
- Splenomegaly ⚖️.
- Progression risk to AML in some patients.
- JAK2 testing = key diagnostic tool in suspected myeloproliferative neoplasms.
Management Implications 💊
- JAK inhibitors (e.g., ruxolitinib) for myelofibrosis and resistant cases.
- Cytoreduction (e.g., hydroxycarbamide) in PV/ET to control counts.
- Aspirin often used in ET and PV for thrombosis prevention (unless contraindicated).
- Ongoing monitoring for:
- Thrombosis / bleeding.
- Progression to acute leukaemia.
- Bone marrow fibrosis.
References 📚
💡 Exam Pearl
Think JAK2 V617F whenever you see:
– PV with raised Hb/Hct 🎯
– ET with platelets >450 ×10⁹/L 🧮
– Splenomegaly with constitutional symptoms 🛌